Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment for COVID-19: An overview
Cristina Stasi, Silvia Fallani, Fabio Voller, et al.
European Journal of Pharmacology (2020) Vol. 889, pp. 173644-173644
Open Access | Times Cited: 327

Showing 1-25 of 327 citing articles:

Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy
Giulia Giordano, Marta Colaneri, Alessandro Di Filippo, et al.
Nature Medicine (2021) Vol. 27, Iss. 6, pp. 993-998
Open Access | Times Cited: 201
Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease
Lukas van de Sand, Maren Bormann, Mira Alt, et al.
Viruses (2021) Vol. 13, Iss. 4, pp. 609-609
Open Access | Times Cited: 162
Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?
Soumya Ghosh, Charné Bornman, Mai M. Zafer
Journal of Infection and Public Health (2021) Vol. 14, Iss. 5, pp. 555-560
Open Access | Times Cited: 155
Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients
Danielle L. da Silva, Camila Mendes de Lima, Vanessa Caroline Randi Magalhães, et al.
Journal of Hospital Infection (2021) Vol. 113, pp. 145-154
Open Access | Times Cited: 135
Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses
Ali A. Rabaan, Shamsah H. Al-Ahmed, Mohammed Garout, et al.
Pathogens (2021) Vol. 10, Iss. 5, pp. 565-565
Open Access | Times Cited: 73
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition
Guillem Macip, Pol Garcia‐Segura, Júlia Mestres‐Truyol, et al.
Medicinal Research Reviews (2021) Vol. 42, Iss. 2, pp. 744-769
Open Access | Times Cited: 67
Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates
Liliana Rodrigues, Renata Bento Cunha, Tatiana Vassilevskaia, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2723-2723
Open Access | Times Cited: 63
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity
Shenghua Gao, Katharina Sylvester, Letian Song, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13343-13364
Closed Access | Times Cited: 63
Mitochondrial health quality control: measurements and interpretation in the framework of predictive, preventive, and personalized medicine
Lenka Koklesová, Alena Mazuráková, Marek Samec, et al.
The EPMA Journal (2022) Vol. 13, Iss. 2, pp. 177-193
Open Access | Times Cited: 56
E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition
Charles N. Serhan, Stephania Libreros, Robert Nshimiyimana
Seminars in Immunology (2022) Vol. 59, pp. 101597-101597
Open Access | Times Cited: 51
SARS-CoV-2: A Master of Immune Evasion
Alberto Rubio‐Casillas, Elrashdy M. Redwan, Vladimir N. Uversky
Biomedicines (2022) Vol. 10, Iss. 6, pp. 1339-1339
Open Access | Times Cited: 50
Classification of lungs infected COVID-19 images based on inception-ResNet
Yunfeng Chen, Ya‐Lan Lin, Xiaodie Xu, et al.
Computer Methods and Programs in Biomedicine (2022) Vol. 225, pp. 107053-107053
Open Access | Times Cited: 48
Coronavirus Infection and Cholesterol Metabolism
Jun Dai, Huan Wang, Ying Liao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
Even patients with mild COVID‐19 symptoms after SARS‐CoV‐2 infection show prolonged altered red blood cell morphology and rheological parameters
Marijke Grau, Lars Ibershoff, Jonas Zacher, et al.
Journal of Cellular and Molecular Medicine (2022) Vol. 26, Iss. 10, pp. 3022-3030
Open Access | Times Cited: 45
Identification of Drug Interaction Adverse Events in Patients With COVID-19
Valeria Conti, Carmine Sellitto, Martina Torsiello, et al.
JAMA Network Open (2022) Vol. 5, Iss. 4, pp. e227970-e227970
Open Access | Times Cited: 41
Exosomal miR-145 and miR-885 Regulate Thrombosis in COVID-19
Jessica Gambardella, Urna Kansakar, Celestino Sardu, et al.
Journal of Pharmacology and Experimental Therapeutics (2022) Vol. 384, Iss. 1, pp. 109-115
Open Access | Times Cited: 38
Solubility of Pholcodine (antitussive drug) in supercritical carbon dioxide: Experimental data and thermodynamic modeling
Gholamhossein Sodeifian, Ratna Surya Alwi, Fariba Razmimanesh
Fluid Phase Equilibria (2022) Vol. 556, pp. 113396-113396
Closed Access | Times Cited: 37
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3664-3702
Open Access | Times Cited: 26
Interrelationship between COVID-19 and Coagulopathy: Pathophysiological and Clinical Evidence
Beatrice Ragnoli, Beatrice Da Re, Alessandra Galantino, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8945-8945
Open Access | Times Cited: 21
Fatal COVID-19 pulmonary disease involves ferroptosis
Baiyu Qiu, Fereshteh Zandkarimi, Anjali Saqi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization
Tania Ciaglia, Vincenzo Vestuto, Veronica Di Sarno, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116128-116128
Open Access | Times Cited: 7
Impact of vaccination status on clinical outcomes of hospitalized COVID-19 patients
Mohsen Gholinataj Jelodar, Samaneh Mirzaei, Fatemeh Saghafi, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7
Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein
Robert J. Ragotte, David Pulido, Francesca R. Donnellan, et al.
mSphere (2021) Vol. 6, Iss. 4
Open Access | Times Cited: 54
Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study*
Charles‐Hervé Vacheron, Alain Lepape, Anne Savey, et al.
Critical Care Medicine (2021) Vol. 50, Iss. 3, pp. 449-459
Open Access | Times Cited: 53
Purification and characterization of the receptor‐binding domain of SARS‐CoV‐2 spike protein from Escherichia coli
Yunxia He, Jinming Qi, Lucheng Xiao, et al.
Engineering in Life Sciences (2021) Vol. 21, Iss. 6, pp. 453-460
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top